The Guerriero Lab works closely with the Breast Tumor Immunology Laboratory (BTIL) at Dana-Farber Cancer Institute. Dr. Elizabeth Mittendorf, MD, PhD launched the BTIL in 2018 and in partnership with Dr. Guerriero they built the laboratory as part of an initiative to be the preeminent breast tumor immunology/immunotherapy program in the country. The laboratory bridges the clinical breast oncology program with the basic and translation breast cancer immunology laboratory efforts at Dana-Farber. Dr. Mittendorf is the Director of the Breast Immuno-Oncology Program and Dr. Guerriero serves as the Director of the Breast Tumor Immunology Laboratory.
The BTIL has a high priority on understanding resistance to T-cell immunotherapy in breast cancer, identification of novel immunotherapy targets, linking pre-clinical work to clinical trials, correlating clinical trial outcomes with changes in the tumor microenvironment and analyzing human tumors to inform pre-clinical work. Drs. Mittendorf and Guerriero co-mentor a number of highly talented research scientists and fellows with the ultimate goal of translating laboratory findings into clinical trials. The major goal is to understand the complex breast tumor microenvironment to design/develop new therapies to enhance patient care. We work closely with the outstanding basic scientists, translational researchers and clinical trialists across the Harvard system to advance the science of our basic investigators to the clinic, then take observations/specimens from the clinic back to the laboratory.